MON-358 Hypercalcemia During Teriparatide Therapy
نویسندگان
چکیده
منابع مشابه
Teriparatide Induced Delayed Persistent Hypercalcemia
Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually within 16 hours of drug administration. Persistent hypercalcemia, although not observed in clinical trials, is rarely reported. The current ca...
متن کاملTherapy of Osteoporosis in Men with Teriparatide
Osteoanabolic therapy is an attractive therapeutic option for men with osteoporosis because it directly stimulates bone formation, an action not shared by any antiresorptive drug. Teriparatide (recombinant human PTH(1-34)) and PTH(1-84) are available in many countries but PTH(1-84) is not available in the United States. Only teriparatide is approved for the treatment of osteoporosis in men. It ...
متن کامل358 Cedraschi.qxd
Background. Chronic low back pain (LBP) accounts for the majority of the disability and costs for LBP. However, the definition of chronicity is unclear. Aim. To elicit practitioners’ definitions of chronic LBP patients, both in general and in the patients they were treating; to assess the most common characteristics of these practitioners’ chronic LBP patients; and to assess the stability of ch...
متن کاملOp-nare130383 358..362
This article introduces the T-RMSD web server (tree-based on root-mean-square deviation), a service allowing the online computation of structure-based protein classification. It has been developed to address the relation between structural and functional similarity in proteins, and it allows a fine-grained structural clustering of a given protein family or group of structurally related proteins...
متن کاملPamidronate therapy for hypercalcemia of childhood malignancy
Background Hypercalcemia is a common complication of adult malignancies, but uncommon in childhood cancers. The mechanism leading to hypercalcemia varies with the primary tumour and can include the following: 1) Increased osteoclastic activity at the site of the tumour in the bone marrow 2) A paraneoplastic phenomenon secondary to PTH-related peptide (PTHrP) secretion or 1,25–dihydroxyvitamin D...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Endocrine Society
سال: 2020
ISSN: 2472-1972
DOI: 10.1210/jendso/bvaa046.1112